Welcome to our dedicated page for Fortrea Holdings news (Ticker: FTRE), a resource for investors and traders seeking the latest updates and insights on Fortrea Holdings stock.
Fortrea Holdings Inc. (NASDAQ: FTRE) is a global contract research organization and provider of clinical development solutions to the life sciences industry. This news page aggregates company press releases and market updates related to FTRE, giving readers a focused view of how Fortrea operates as a public company and clinical development partner.
According to its own descriptions, Fortrea partners with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies. News about the company frequently highlights its work in phase I–IV clinical trial management, clinical pharmacology and consulting services, as well as its experience across more than 20 therapeutic areas and operations in about 100 countries.
Visitors can expect news items covering a range of topics, including quarterly and year-to-date financial results, guidance updates, cost-saving initiatives, and capital structure actions such as tender offers for senior secured notes. Fortrea also issues releases on leadership and governance developments, such as board appointments and executive hires, and on strategic collaborations with other organizations involved in areas like cell and gene therapy development and delivery.
Because Fortrea is listed on The NASDAQ Stock Market LLC under the symbol FTRE, its news flow also includes announcements about participation in healthcare and investor conferences, earnings calls and webcasts. Together, these updates provide insight into how Fortrea manages its clinical development services business, interacts with the investment community and responds to developments in its operating environment.
For investors, analysts and industry observers, following FTRE news offers a way to monitor the company’s financial reporting, governance changes, collaborations and other material events that Fortrea discloses through press releases and related communications.
Fortrea (Nasdaq: FTRE) will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026.
The company will host a conference call at 8:00 am ET the same day with a Q&A. Participants should register on the Fortrea Investor Relations website, join at least 10 minutes early, and can access a live webcast. A replay will be posted in the events and presentations section.
Fortrea (Nasdaq: FTRE) updated its presentation time at the J.P. Morgan Annual Healthcare Conference to 11:15 am PST on Tuesday, January 13, 2026. CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations Tracy Krumme will participate. A live webcast and replay will be available via the company’s Investor Relations "Events" page. Investors seeking one-on-one meetings should contact their banking representatives.
Fortrea (Nasdaq: FTRE) announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP Investor Relations Tracy Krumme will present at the J.P. Morgan Annual Healthcare Conference in San Francisco.
The presentation and Q&A are scheduled for Tuesday, January 13, 2025 at 5:15 pm PST. A live webcast and replay will be available in the company’s Events section on Fortrea’s Investor Relations website. Investors seeking one-on-one meetings are asked to contact their banking representatives.
Fortrea (Nasdaq: FTRE) announced on December 10, 2025 the grant of inducement restricted stock units (RSUs) to two newly hired employees. The award totals 245,000 RSUs granted on December 10, 2025.
The RSUs vest in three equal annual installments beginning December 10, 2026, subject to continuous employment through each vesting date, and are governed by the company’s Amended and Restated 2025 Inducement Award Plan and the applicable award agreements. The grants were made under Nasdaq Listing Rule 5635(c)(4) as inducements to employment.
SCTbio and Fortrea (FTRE) announced a strategic collaboration on December 4, 2025 to align CDMO manufacturing and CRO clinical development for cell and gene therapies. The partnership aims to streamline development timelines, harmonize GMP manufacturing readiness with trial logistics, and reduce program risk by enabling early protocol alignment, supply‑chain resilience, and coordinated planning from first‑in‑human trials toward commercialization.
The agreement stresses synchronized execution across manufacturing, apheresis, viral vectors and global clinical operations to accelerate delivery of advanced therapies to patients.
Fortrea (Nasdaq: FTRE) announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP Investor Relations Tracy Krumme will participate in two December healthcare conferences in Miami.
Details: Citi Global Healthcare Conference — Tuesday, December 2, 2025 at 1:00 pm ET (fireside chat, webcast). Evercore 8th Annual Healthcare Conference — Wednesday, December 3, 2025 at 10:50 am ET (fireside chat, webcast).
Live webcasts and replays will be available in the Events section of Fortrea’s Investor Relations website. Investors seeking one-on-one meetings should contact their banking representatives.
Fortrea (Nasdaq: FTRE) completed a tender offer, purchasing $75,743,000 aggregate principal of its 7.500% Senior Secured Notes due 2030 on November 21, 2025.
The repurchase reduced principal outstanding on the Notes from $570,000,000 to $494,257,000. The company said it funded the transaction entirely with cash on hand and that the Tender Offer satisfied a requirement related to its June 2024 divestiture of Fortrea Patient Access and Endpoint Clinical businesses.
U.S. Bank Trust reported that valid tenders exceeded $75,744,000; Fortrea accepted $75,743,000 based on a Final Proration Factor of 0.154199 and rounding rules.
Fortrea (Nasdaq: FTRE) announced on November 17, 2025 the appointment of Agnieszka M. Gallagher as general counsel. Gallagher will lead the company’s legal strategy and operations, serve as corporate secretary and chief compliance officer, and join Fortrea’s leadership team.
Gallagher brings more than 25 years of experience across life sciences, biotech, diagnostics, pharmaceutical and medtech sectors, including roles as chief legal officer at Standard Biotools where she was involved in its merger with SomaLogic, and senior legal and compliance positions at Orasure, Alnylam, ViiV Healthcare, GSK Biologics, Sandoz, Medtronic and Pfizer. She succeeds J. Stillman Hanson, who is leaving after a planned transition period.
Fortrea (Nasdaq: FTRE) reported third-quarter 2025 continuing-operations results with Q3 revenue of $701.3M and a Q3 adjusted EBITDA of $50.7M. GAAP net loss for the quarter was $15.9M and adjusted net income was $11.7M (diluted EPS $0.12). Backlog stood at $7,644M and book-to-bill was 1.13x. Year-to-date revenue was $2,062.9M, while YTD GAAP net loss was $953.7M, which included a $797.9M non-cash goodwill impairment impacting EPS by $8.81. The company raised full-year 2025 revenue guidance to $2,700M–$2,750M and narrowed adjusted EBITDA guidance to $175M–$195M.
Management said cost-saving initiatives remain on track and there were no impairment indicators in Q3.
Fortrea (Nasdaq: FTRE) commenced a cash tender offer to purchase up to $75,744,000 aggregate principal of its outstanding 7.500% Senior Secured Notes due 2030, effective October 20, 2025. The offer price is $1,000 per $1,000 principal plus accrued interest; the Tender Offer will expire at 5:00 p.m. New York time on November 18, 2025 unless extended.
The principal purpose is to comply with indenture covenants tied to net proceeds from Fortrea’s June 2024 divestiture; funding is expected from cash on hand and/or other liquidity sources. Acceptance is subject to conditions and possible proration. Holders may withdraw tenders prior to expiration.
FAQ
What is the current stock price of Fortrea Holdings (FTRE)?
What is the market cap of Fortrea Holdings (FTRE)?
